Medical News

Low CD4 Cell Count Increases the Risk of Several Cancers After Starting HIV Therapy

June 13, 2013

Researchers investigated the incidence and timing of cancer diagnoses among patients who began triple-drug antiretroviral therapy (ART) between 1996 and 2011. The researchers reviewed the records of approximately 11,500 persons, examined trends in cancer incidence for up to 10 years after treatment initiation, and investigated factors associated with a cancer diagnosis.

The researchers divided cancers into different categories: AIDS-defining cancers (Kaposi's sarcoma, non-Hodgkin's lymphoma, and cervical cancer); non-AIDS-defining cancers; lymphomas; cancers related to human papillomavirus (HPV); other virus-related cancers; and virus-unrelated cancers. Patients were mostly male (80 percent) and racially diverse. Median age at which they started ART was 38 years and most patients were immunosuppressed when they began treatment. The researchers followed patients for a median of three years and followed 10 percent of patients for 10 years.

Data showed 457 cancer diagnoses in 46,318 person-years of follow-up, which provided an incidence rate of 987 cases per 100,000 person-years.

Incidence of AIDS-defining cancers was similar to that for non-AIDS defining cancers (515 versus 466 per 100,000 person years). Kaposi's sarcoma was the most common AIDS-defining cancer. The most common non-AIDS cancer among women was breast cancer and among men was anal cancer. Timing of cancer diagnosis differed based on whether or not the cancer was AIDS-defining. Incidence of Kaposi's was very high in the first six months after therapy, fell during the second six months, and remained low during the follow-up. Lymphomas followed the same trend. Incidence of non-AIDS defining cancers increased with longer duration of follow-up, increasing 7 percent for each additional year of treatment. Each 10-year age increase doubled the risk of non-lymphoma cancers and HPV-related cancers. CD4 cell count at the time of therapy initiation was associated with cancer risk -- low CD4 cell count was associated with lymphomas and HPV-related cancers.

Results show that ART improvements did not affect the incidence of cancer in patients with HIV infection. The researchers contended that results emphasized the need for early HIV diagnosis, prevention measures such as vaccines, and cancer screening for persons with HIV.

The full report, "Incidence and Timing of Cancer in HIV-Infected Individuals Following Initiation of Combination Antiretroviral Therapy," was published online in the journal Clinical Infectious Diseases (2013; doi: 10.1093/cid/cit369).

Back to other news for June 2013

Adapted from:
06.12.2013; Michael Carter

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.


Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.